Abstract
Nicotinamide phosphoribosyltransferase (NAMPT), an enzyme taking part in main NAD biosynthetic pathway, is an attractive target for anticancer therapy. The purpose of our study is to find novel NAMPT inhibitors based on in silico drug discovery means including the generation of 3D-QSAR models, and virtual screening techniques. Firstly, ten pharmacophore models were generated by Catalyst/HypoGen algorithm. Hypo1 with high correl value (0.96), large Δcost (77.77), and low root mean square deviation (0.81), featured by four chemical features was selected as the best one. Subsequently, Hypo1 was validated through test set prediction and Fischer’s randomization methodologies. Then we screened some public compound libraries (Asinex, Ibscreen and Natural products database) using Hypo1 for a 3D query. The screened hits were further refined by Lipinski’s rule of five, ADMET properties as well as molecular docking studies. Finally, six molecules with diverse scaffolds exhibited the right pharmacophore features and good binding modes between the receptor and ligands, and were selected as possible candidates against NAMPT for further study.
Keywords: 3D QSAR models, Catalyst/HypoGen, molecular docking, NAMPT, virtual screening.
Combinatorial Chemistry & High Throughput Screening
Title:Discovery of Novel NAMPT Inhibitors Based on Pharmacophore Modeling and Virtual Screening Techniques
Volume: 17 Issue: 10
Author(s): Qianying Yi, Lu Zhou, Xin Shao, Taijin Wang, Guangkai Bao, Huanhuan Shi, Suwen Zhou, Xiaoli Li and Yahui Tian
Affiliation:
Keywords: 3D QSAR models, Catalyst/HypoGen, molecular docking, NAMPT, virtual screening.
Abstract: Nicotinamide phosphoribosyltransferase (NAMPT), an enzyme taking part in main NAD biosynthetic pathway, is an attractive target for anticancer therapy. The purpose of our study is to find novel NAMPT inhibitors based on in silico drug discovery means including the generation of 3D-QSAR models, and virtual screening techniques. Firstly, ten pharmacophore models were generated by Catalyst/HypoGen algorithm. Hypo1 with high correl value (0.96), large Δcost (77.77), and low root mean square deviation (0.81), featured by four chemical features was selected as the best one. Subsequently, Hypo1 was validated through test set prediction and Fischer’s randomization methodologies. Then we screened some public compound libraries (Asinex, Ibscreen and Natural products database) using Hypo1 for a 3D query. The screened hits were further refined by Lipinski’s rule of five, ADMET properties as well as molecular docking studies. Finally, six molecules with diverse scaffolds exhibited the right pharmacophore features and good binding modes between the receptor and ligands, and were selected as possible candidates against NAMPT for further study.
Export Options
About this article
Cite this article as:
Yi Qianying, Zhou Lu, Shao Xin, Wang Taijin, Bao Guangkai, Shi Huanhuan, Zhou Suwen, Li Xiaoli and Tian Yahui, Discovery of Novel NAMPT Inhibitors Based on Pharmacophore Modeling and Virtual Screening Techniques, Combinatorial Chemistry & High Throughput Screening 2014; 17 (10) . https://dx.doi.org/10.2174/1386207317666141121124139
DOI https://dx.doi.org/10.2174/1386207317666141121124139 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Quantitative Structure-Activity Relationship Studies: Understanding the Mechanism of Tyrosine Kinase Inhibition
Current Enzyme Inhibition Cellular Actions of Nesfatin-1 on Hypothalamic and Medullary Neurons
Current Pharmaceutical Design Cytokine Profile in Patients Infected with Anisakis simplex in Endemic Areas: Dietary Intervention with Polyphenols: A Working Hypothesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Yeast Network and Report of New Stochastic-Credibility Cell Cycle Models
Current Bioinformatics New Horizons in the Etiopathogenesis and Non-Invasive Diagnosis of Endometriosis.
Current Molecular Medicine Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry The Use of Radioactive Iodine in the Management of Hyperthyroidism in Children
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Brain-Skin Connection: Stress, Inflammation and Skin Aging
Inflammation & Allergy - Drug Targets (Discontinued) Vitamin D Therapy in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Structure and Function of the Human Nuclear Xenobiotic Receptor PXR
Current Drug Metabolism RAGE: A Single Receptor for Several Ligands and Different Cellular Responses: The Case of Certain S100 Proteins
Current Molecular Medicine Recent Studies on Aromatase and Sulfatase Involved in Breast Cancer and their Inhibitors
Current Enzyme Inhibition Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry New Peptidic GnRH Antagonists Offer a Broad Range of Therapeutic Applications
Letters in Drug Design & Discovery Developing Effective Therapy for Duchenne Muscular Dystrophy (DMD): Challenges and Promises
Current Chemical Biology Vitamin, Mineral, and Drug Absorption Following Bariatric Surgery
Current Drug Metabolism Omentin: Linking Metabolic Syndrome and Cardiovascular Disease
Current Vascular Pharmacology Applications of Circadian Metabolomics
Current Metabolomics Cushing's Syndrome and Steroid Dementia
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Translating Cancer Biomarker Discoveries to Clinical Tests: What should be Considered?
Recent Patents on Biomarkers